Pharus

Pharus, Inc., a spin-off from Quark Biosciences headquartered in Hsinchu, Taiwan, has offices in Hsinchu and Hong Kong and plans to open its U.S. office in Los Angeles, California. Pharus, Inc. is an innovative healthcare company with the vision of becoming the leading provider of affordable, widely applicable liquid biopsy tests for the early detection of various types of cancers, aiming for a future where all cancers can be treated early for better outcomes. Backed by leading investors including CK Life Sciences and CK Hutchison, the company is currently developing its OncoSweep™ Multi-Cancer Early Detection (MCED) and single-cancer liquid biopsy tests to help inform individuals and ultimately save lives.